- Home
- INCY vs KMX Comparison
INCY vs KMX Comparison
Compare INCY & KMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- KMX
- Stock Information
- Founded
- INCY 1991
- KMX 1993
- Country
- INCY United States
- KMX United States
- Employees
- INCY N/A
- KMX N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- KMX Retail-Auto Dealers and Gas Stations
- Sector
- INCY Health Care
- KMX Consumer Discretionary
- Exchange
- INCY Nasdaq
- KMX Nasdaq
- Market Cap
- INCY 13.4B
- KMX 12.5B
- IPO Year
- INCY 1993
- KMX 1997
- Fundamental
- Price
- INCY $68.07
- KMX $72.78
- Analyst Decision
- INCY Buy
- KMX Buy
- Analyst Count
- INCY 19
- KMX 11
- Target Price
- INCY $74.38
- KMX $90.82
- AVG Volume (30 Days)
- INCY 1.8M
- KMX 1.7M
- Earning Date
- INCY 04-29-2025
- KMX 04-10-2025
- Dividend Yield
- INCY N/A
- KMX N/A
- EPS Growth
- INCY N/A
- KMX N/A
- EPS
- INCY 0.15
- KMX 2.93
- Revenue
- INCY $4,241,216,999.00
- KMX $27,796,200,000.00
- Revenue This Year
- INCY $12.23
- KMX N/A
- Revenue Next Year
- INCY $8.89
- KMX $3.51
- P/E Ratio
- INCY $454.93
- KMX $24.76
- Revenue Growth
- INCY 14.76
- KMX N/A
- 52 Week Low
- INCY $50.35
- KMX $65.83
- 52 Week High
- INCY $83.95
- KMX $91.25
- Technical
- Relative Strength Index (RSI)
- INCY 38.27
- KMX 23.26
- Support Level
- INCY $68.17
- KMX $81.35
- Resistance Level
- INCY $72.81
- KMX $84.49
- Average True Range (ATR)
- INCY 2.29
- KMX 2.50
- MACD
- INCY -0.32
- KMX -1.26
- Stochastic Oscillator
- INCY 8.61
- KMX 11.40
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About KMX CarMax Inc
CarMax sells, finances, and services used and new cars through a chain of around 250 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue (79% in fiscal 2024 due to the chip shortage) and wholesale about 13% (19% in fiscal 2024), with the remaining portion composed of extended service plans and repair. In fiscal 2024, the company retailed and wholesaled 765,572, and 546,331 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the US but still estimates that it had only about 3.7% US market share of vehicles 0-10 years old in 2023. It seeks over 5% share a few years from now. CarMax is based in Richmond, Virginia.